The biopharmaceutical industry invests billions of dollars annually
into clinical research to address a range of debilitating respiratory
conditions. Phil Lake at ERT discusses how the active management
of data quality reduces variability in the outcomes, as well as bringing
greater confidence in the drug’s effect, ability to identify the true
responders, and faster drug development.